Bristol Myers Squibb Announces $2.3 Billion Manufacturing Site in Houston
Bristol Myers Squibb is investing $2.3 billion to establish a new manufacturing site in Houston, signifying a significant commitment to the city.
Houston, TX, August 10, 2026 — Bristol Myers Squibb, a global biopharmaceutical company, has announced plans to invest $2.3 billion in the establishment of a new manufacturing site in Houston, Texas. This substantial investment marks a significant commitment to the city and is expected to bolster the company’s manufacturing capabilities.
The development of the new facility represents a major expansion for Bristol Myers Squibb. While specific details regarding the timeline for construction and the projected operational start date of the new site were not provided, the company’s financial commitment underscores the strategic importance of this Houston location. The purpose of the manufacturing site is to support the production of the company’s pharmaceutical products.
The decision to build a new manufacturing site in Houston is anticipated to have economic implications for the region. Further information regarding job creation and the specific types of manufacturing to be undertaken at the facility was not immediately available. The company’s investment highlights the growing life sciences sector in Houston.
Story summarized from the original created by Google News on news.google.com, see more information here.
